Chandra P. Belani, MD
The International Association for the Study of Lung Cancer (IASLC) has named Chandra P. Belani, MD, as its new Chief Science Officer. In this position, Dr. Belani will direct, guide, and support the IASLC scientific strategy, including, but not limited to, scientific research projects, publications, educational content for conferences, and educational offerings for members. Dr. Belani will also serve as a spokesperson for IASLC at conferences, with the media, and in meetings with industry partners and donors.
Dr. Belani is currently Professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the Penn State Hershey Medical Center in Hershey, Pennsylvania. Dr. Belani also worked in several positions at the Penn State College of Medicine as Deputy Director of the Penn State Cancer Institute, Associate Director of Clinical Research, and Director of the Lung Cancer Program.
Prior to that, Dr. Belani served in multiple leadership positions at the University of Pittsburgh Cancer Institute, including Director of Community Oncology, Co-Director of the Lung Cancer Program, and Co-Director of the Experimental Therapeutics Program. His research accomplishments in the areas of lung cancer and new drug development have led to changes in treatment paradigms. Interacting with experts across the world, Dr. Belani has developed and identified novel therapeutic strategies that have been approved and adopted as “standards of care” in the management of lung cancer.
Dr. Belani is a graduate of Sawai Man Singh Medical College, University of Rajasthan, Jaipur, India. After completing his residency in internal medicine, he was a fellow in hematology and oncology at the University of Maryland. Dr. Belani joined the faculty at the University of Maryland Cancer Center thereafter and served as Assistant Professor of Medicine and Oncology as well as Director of Thoracic Oncology at the University of Maryland Medical School in Baltimore. He is board certified by the American Board of Internal Medicine and the American Board of Internal Medicine Oncology and holds memberships in ASCO, the American Association for Cancer Research, and IASLC. ■